| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Aspire Biopharma Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| Fr | Aspire Biopharma to acquire auto parts maker for $30 million | 3 | Investing.com | ||
| Fr | Aspire Biopharma Holdings, Inc.: Aspire Biopharma Announces Signing of Definitive Share Purchase Agreement to Acquire Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue | 702 | ACCESS Newswire | Adds an established global brand with scale in large and growing markets driven by trends in vehicle and mobility control systemsAcquisition significantly accelerates Aspire's revenue, earnings growth... ► Artikel lesen | |
| 28.05. | Aspire Biopharma Holdings, Inc.: Aspire Biopharma Issues Shareholder Letter | 476 | ACCESS Newswire | ESTERO, FL / ACCESS Newswire / May 28, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery... ► Artikel lesen | |
| 27.05. | Aspire Biopharma Holdings, Inc.: Aspire Biopharma's BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of Members | 428 | ACCESS Newswire | ESTERO, FL / ACCESS Newswire / May 27, 2026 / Aspire Biopharma Holdings, Inc.'s (Nasdaq:ASBP) ("Aspire" or the "Company") wholly owned subsidiary Buzz Bomb Caffeine Company LC is proud to announce a... ► Artikel lesen | |
| 14.05. | Aspire Biopharma Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.05. | Aspire Biopharma to implement 1-for-30 reverse stock split | 3 | Investing.com | ||
| 07.05. | Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio | 423 | ACCESS Newswire | ESTERO, FL / ACCESS Newswire / May 7, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today... ► Artikel lesen | |
| ASPIRE BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 27.04. | Aspire Biopharma authorizes $5 million stock buyback program | 7 | Investing.com | ||
| 27.04. | Aspire Biopharma genehmigt Aktienrückkaufprogramm über 5 Millionen US-Dollar | 4 | Investing.com Deutsch | ||
| 27.04. | Aspire Biopharma announces $5M share repurchase program | 3 | Seeking Alpha | ||
| 27.04. | Aspire Biopharma Holdings, Inc.: Aspire Biopharma Announces $5.0 Million Share Repurchase Program | 586 | ACCESS Newswire | ESTERO, FL / ACCESS Newswire / April 27, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery... ► Artikel lesen | |
| 20.04. | Aspire Biopharma: $21 Million Private Placement Closed To Support DCS Acquisition And Growth Strategy | 5 | pulse2.com | ||
| 20.04. | Aspire Biopharma Holdings, Inc.: Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition | 431 | ACCESS Newswire | Company secures Commitment Letter from a leading financial institution of up to $22.5M to finance proposed acquisition of Dura Control Systems (DCS)LOI to acquire DCS, a leading global automotive supplier... ► Artikel lesen | |
| 17.04. | Aspire Biopharma Holdings, Inc.: Aspire Biopharma's Buzz Bomb Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo | 876 | ACCESS Newswire | Elite Ultra-Marathoner targets her second World Record in two months following historicUltra Jackpot 100 Win ESTERO, FL / ACCESS Newswire / April 17, 2026 / Aspire Biopharma Holdings, Inc.'s (NASDAQ:ASBP)... ► Artikel lesen | |
| 16.04. | Aspire Biopharma: Aktionäre genehmigen Aktienzusammenlegung und Kapitalerhöhung | 5 | Investing.com Deutsch | ||
| 16.04. | Aspire Biopharma signs letter of intent to acquire DCS for $30M | 3 | Investing.com | ||
| 16.04. | Aspire Biopharma plant Übernahme von Automobilzulieferer DCS für 30 Mio. US-Dollar | 5 | Investing.com Deutsch | ||
| 16.04. | Aspire Biopharma Holdings, Inc.: Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue | 517 | ACCESS Newswire | ESTERO, FL / ACCESS Newswire / April 16, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery... ► Artikel lesen | |
| 15.04. | Aspire Biopharma Holdings, Inc.: Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion | 337 | ACCESS Newswire | Interwest to Drive Regional Growth for BUZZ BOMB Across Major Grocery and Convenience Channels ESTERO, FL / ACCESS Newswire / April 15, 2026 / Aspire Biopharma Holdings, Inc.'s (Nasdaq:ASBP) ("Aspire"... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APTORUM GROUP | 0,847 | -1,31 % | Aptorum Group Ltd: Aptorum Group Announces Shareholder Approval of Proposed Merger with DiamiR Biosciences | NEW YORK, NY, June 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company dedicated to addressing unmet medical needs, today announced... ► Artikel lesen | |
| CHINA HEALTH GROUP INC | 0,002 | -20,00 % | C HEALTH GP (08225): SUPPLEMENTAL ANNOUNCEMENT DISCLOSURES RELATING TO SHARE OPTION SCHEME AND CONTINUING CONNECTED TRANSACTION | ||
| BAYER | 36,340 | +1,54 % | EQS-PVR: Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Bayer Aktiengesellschaft
Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
08.06.2026... ► Artikel lesen | |
| MERCK KGAA | 133,95 | -1,07 % | EQS-PVR: Merck KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Merck KGaA
Merck KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
08.06.2026 / 16:57 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 60,93 | -0,03 % | Bright Minds Biosciences Announces Closing of US$175 Million Public Offering | NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 12,380 | 0,00 % | Generate:Biomedicines: Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update | SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first... ► Artikel lesen | |
| NOVO NORDISK | 38,470 | +2,26 % | JPMORGAN stuft NOVO NORDISK auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Novo Nordisk mit einem Kursziel von 250 dänischen Kronen auf "Neutral" belassen. Analyst Richard Vosser ging am Montag auf die... ► Artikel lesen | |
| ELI LILLY | 981,30 | +0,22 % | Eli Lilly-Aktie: Geht die Erfolgsgeschichte noch weiter? | Die Eli Lilly-Aktie beendete bereits die letzte Handelswoche auf einem neuen Allzeithoch und legt zum Wochenstart noch mal eine Schippe drauf. Am Montagmorgen ist der US-Pharmakonzern mit einem Kursplus... ► Artikel lesen | |
| PFIZER | 22,615 | -0,11 % | Pharma & Biotechnologie: 11 Milliarden US-Dollar für die Zukunft: GSK greift im Krebsmarkt an | © Foto: Nikos Pekiaridis - NurPhotoGSK übernimmt Nuvalent für 10,6 Milliarden US-Dollar und stärkt sein Krebsgeschäft. Der Rekorddeal soll Wachstum sichern und Patentrisiken abfedern.Der britische Pharmakonzern... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,175 | +0,12 % | Aquestive Therapeutics, Inc. - 8-K, Current Report | ||
| GILEAD SCIENCES | 108,48 | -0,04 % | Nabelschnurzellen aus Dresden bringen neuen Schwung in die Zelltherapie-Debatte. | ||
| ETON PHARMACEUTICALS | 31,550 | -0,13 % | Eton Pharmaceuticals, Inc. - 8-K, Current Report | ||
| NOVARTIS | 132,56 | +0,21 % | DEUTSCHE BANK RESEARCH stuft NOVARTIS AG auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Novartis mit einem Kursziel von 135 Franken auf "Buy" belassen. Dies schrieb Emmanuel Papadakis in seinem am Dienstag vorliegenden... ► Artikel lesen | |
| ATRIUM THERAPEUTICS | 12,370 | 0,00 % | Atrium Therapeutics Reports First Quarter 2026 Financial Results | SAN DIEGO, May 14, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 14,290 | +0,07 % | Kazia Therapeutics Limited: Kazia Therapeutics Appoints James Levine as Chief Financial Officer | SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company... ► Artikel lesen |